Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of influenza
3.2.1.2 Rising awareness and adoption of influenza medications
3.2.1.3 Increasing research and development activities related to influenza drugs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with antiviral drugs
3.2.2.2 High cost associated with drug development
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Antiviral drugs
5.2.1 Single antiviral drugs
5.2.2 Combination antiviral drugs
5.3 Antihistamines
5.4 Analgesics
5.5 Antipyretics
Chapter 6 Market Estimates and Forecast, By Influenza Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Influenza A
6.3 Influenza B
Chapter 7 Market Estimates and Forecast, By Age Group, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Adults
7.3 Pediatric
7.4 Geriatric
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Inhaled
8.4 Intravenous
Chapter 9 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Branded
9.3 Generic
Chapter 10 Market Estimates and Forecast, By Medication, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 Prescription
10.3 OTC
Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
11.1 Key trends
11.2 Hospital pharmacies
11.3 Retail pharmacies
11.4 Online pharmacies
Chapter 12 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
12.1 Key trends
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Spain
12.3.5 Italy
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Australia
12.4.5 Rest of Asia Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest of Latin America
12.6 Middle East and Africa
12.6.1 South Africa
12.6.2 Saudi Arabia
12.6.3 Rest of Middle East and Africa
Chapter 13 Company Profiles
13.1 AstraZeneca plc
13.2 BioCryst Pharmaceuticals, Inc.
13.3 Daiichi Sankyo Company
13.4 F. Hoffmann-La Roche AG
13.5 GlaxoSmithKline plc
13.6 Lupin
13.7 NATCO Pharma Limited
13.8 Novartis AG
13.9 Sanofi
13.10 Teva Pharmaceutical Industries Ltd.
